Cargando…

Effects of bradykinin on venous capacitance in health and treated chronic heart failure

In the present study, we investigated the effects of basal and intra-arterial infusion of bradykinin on unstressed forearm vascular volume (a measure of venous tone) and blood flow in healthy volunteers (n=20) and in chronic heart failure patients treated with ACEIs [ACE (angiotensin-converting enzy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunaruwan, Prasad, Maher, Abdul, Williams, Lynne, Sharman, James, Schmitt, Matthias, Campbell, Ross, Frenneaux, Michael
Formato: Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2636358/
https://www.ncbi.nlm.nih.gov/pubmed/18798730
http://dx.doi.org/10.1042/CS20080096
_version_ 1782164291169812480
author Gunaruwan, Prasad
Maher, Abdul
Williams, Lynne
Sharman, James
Schmitt, Matthias
Campbell, Ross
Frenneaux, Michael
author_facet Gunaruwan, Prasad
Maher, Abdul
Williams, Lynne
Sharman, James
Schmitt, Matthias
Campbell, Ross
Frenneaux, Michael
author_sort Gunaruwan, Prasad
collection PubMed
description In the present study, we investigated the effects of basal and intra-arterial infusion of bradykinin on unstressed forearm vascular volume (a measure of venous tone) and blood flow in healthy volunteers (n=20) and in chronic heart failure patients treated with ACEIs [ACE (angiotensin-converting enzyme) inhibitors] (n=16) and ARBs (angiotensin receptor blockers) (n=14). We used radionuclide plethysmography to examine the effects of bradykinin and of the bradykinin antagonists B9340 [B1 (type 1)/B2 (type 2) receptor antagonist] and HOE140 (B2 antagonist). Bradykinin infusion increased unstressed forearm vascular volume in a similar dose-dependent manner in healthy volunteers and ARB-treated CHF patients (healthy volunteers maximum 12.3±2.1%, P<0.001 compared with baseline; ARB-treated CHF patients maximum 9.3±3.3%, P<0.05 compared with baseline; P=not significant for difference between groups), but the increase in unstressed volume in ACEI-treated CHF patients was higher (maximum 28.8±7.8%, P<0.001 compared with baseline; P<0.05 for the difference between groups). In contrast, while the increase in blood flow in healthy volunteers (maximum 362±9%, P<0.001) and in ACEI-treated CHF patients (maximum 376±12%, P<0.001) was similar (P=not significant for the difference between groups), the increase in ARB-treated CHF patients was less (maximum 335±7%, P<0.001; P<0.05 for the difference between groups). Infusion of each receptor antagonist alone similarly reduced basal unstressed volume and blood flow in ACEI-treated CHF patients, but not in healthy volunteers or ARB-treated CHF patients. In conclusion, bradykinin does not contribute to basal venous tone in health, but in ACEI-treated chronic heart failure it does. In ARB-treated heart failure, venous responses to bradykinin are preserved but arterial responses are reduced compared with healthy controls. Bradykinin-mediated vascular responses in both health and heart failure are mediated by the B2, rather than the B1, receptor.
format Text
id pubmed-2636358
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-26363582009-02-10 Effects of bradykinin on venous capacitance in health and treated chronic heart failure Gunaruwan, Prasad Maher, Abdul Williams, Lynne Sharman, James Schmitt, Matthias Campbell, Ross Frenneaux, Michael Clin Sci (Lond) Research Article In the present study, we investigated the effects of basal and intra-arterial infusion of bradykinin on unstressed forearm vascular volume (a measure of venous tone) and blood flow in healthy volunteers (n=20) and in chronic heart failure patients treated with ACEIs [ACE (angiotensin-converting enzyme) inhibitors] (n=16) and ARBs (angiotensin receptor blockers) (n=14). We used radionuclide plethysmography to examine the effects of bradykinin and of the bradykinin antagonists B9340 [B1 (type 1)/B2 (type 2) receptor antagonist] and HOE140 (B2 antagonist). Bradykinin infusion increased unstressed forearm vascular volume in a similar dose-dependent manner in healthy volunteers and ARB-treated CHF patients (healthy volunteers maximum 12.3±2.1%, P<0.001 compared with baseline; ARB-treated CHF patients maximum 9.3±3.3%, P<0.05 compared with baseline; P=not significant for difference between groups), but the increase in unstressed volume in ACEI-treated CHF patients was higher (maximum 28.8±7.8%, P<0.001 compared with baseline; P<0.05 for the difference between groups). In contrast, while the increase in blood flow in healthy volunteers (maximum 362±9%, P<0.001) and in ACEI-treated CHF patients (maximum 376±12%, P<0.001) was similar (P=not significant for the difference between groups), the increase in ARB-treated CHF patients was less (maximum 335±7%, P<0.001; P<0.05 for the difference between groups). Infusion of each receptor antagonist alone similarly reduced basal unstressed volume and blood flow in ACEI-treated CHF patients, but not in healthy volunteers or ARB-treated CHF patients. In conclusion, bradykinin does not contribute to basal venous tone in health, but in ACEI-treated chronic heart failure it does. In ARB-treated heart failure, venous responses to bradykinin are preserved but arterial responses are reduced compared with healthy controls. Bradykinin-mediated vascular responses in both health and heart failure are mediated by the B2, rather than the B1, receptor. Portland Press Ltd. 2009-02-02 2009-03-01 /pmc/articles/PMC2636358/ /pubmed/18798730 http://dx.doi.org/10.1042/CS20080096 Text en © 2009 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by-nc/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gunaruwan, Prasad
Maher, Abdul
Williams, Lynne
Sharman, James
Schmitt, Matthias
Campbell, Ross
Frenneaux, Michael
Effects of bradykinin on venous capacitance in health and treated chronic heart failure
title Effects of bradykinin on venous capacitance in health and treated chronic heart failure
title_full Effects of bradykinin on venous capacitance in health and treated chronic heart failure
title_fullStr Effects of bradykinin on venous capacitance in health and treated chronic heart failure
title_full_unstemmed Effects of bradykinin on venous capacitance in health and treated chronic heart failure
title_short Effects of bradykinin on venous capacitance in health and treated chronic heart failure
title_sort effects of bradykinin on venous capacitance in health and treated chronic heart failure
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2636358/
https://www.ncbi.nlm.nih.gov/pubmed/18798730
http://dx.doi.org/10.1042/CS20080096
work_keys_str_mv AT gunaruwanprasad effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure
AT maherabdul effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure
AT williamslynne effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure
AT sharmanjames effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure
AT schmittmatthias effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure
AT campbellross effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure
AT frenneauxmichael effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure